secwatch.observer — SEC 8-K summary
======================================

Issuer:     Eton Pharmaceuticals, Inc. (ETON)
CIK:        0001710340
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0001437749-25-016468
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eton Q1 revenue $17.3M (+117% YoY); product sales $14.0M (+76%); Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M
--------------------------------------------------------------------------------

- Q1 2025 product sales $14.0M, 76% growth YoY; 17th straight quarter of sequential growth.
- GAAP net loss $(0.06) per share; Non-GAAP EPS $0.07; Adjusted EBITDA $3.7M.
- Relaunched INCRELEX (ultra-rare pediatric endocrinology) and GALZIN (Wilson disease); ET-400 NDA PDUFA May 28.
- Submitted NDA for ET-600 (desmopressin oral solution) after positive pivotal study; expects 10-month FDA review.
- Cash $17.4M; generated $2.1M operating cash flow; expects to exit 2025 at ~$80M annual revenue run rate.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/0001437749-25-016468-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1710340/000143774925016468/eton20250502_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-016468

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer